Actos and Bladder Cancer
Seeger Weiss is investigating reports of complications associated with Actos. Prescribed for the treatment in persons with Type-2 diabetes, the drug Actos has been under investigation from a variety of sources as a possible cause of bladder cancer. In recent news the governments of both Germany and France have pulled the medication from the shelves and have stopped all sales of the drug.
Actos is prescribed for adults with Type-2 diabetes and works to maintain proper levels of sugar. It prevents the liver from producing more sugar than is necessary and allows more efficient use of the insulin that is made in the body. Actos is usually prescribed in combination with changes in dietary habits. It is not intended for those with juvenile diabetes or diabetic ketoacidosis.
Actos comes with a series of health warnings that mainly address the possibility of heart failure and lactic acidosis. There is no specific mention of bladder cancer or diabetic macular edema.
Studies Point To Link Between Actos And Bladder Cancer
The banning of Actos in France and Germany are the latest news in a series of reports made by various scientific boards in the past decade. Complaints of heart problems, fragile bones and serious eyesight conditions had been made for years by patients taking the drug, and in 2007 a major study was concluded that compared the possible health risks in persons taking either Actos or the popular drug Avandia. This study was done using patients on Medicare and concluded that the side effects often linked to Avandia, primarily heart failure, cardiovascular disease and stroke, did not seem to be present in those taking Actos. In May 2011, however, new evidence emerged that supported the link between Actos and the development of bladder cancer.
Independent European Studies
In June 2011 an official report from a scientific study group in Europe found that of the 155,000 patients monitored approximately one fifth of those developing bladder cancer had been taking the drug Actos. This resulted in a nationwide recall and banning of the medication in both France and Germany, and the news of this halting of sales prompted individuals elsewhere to take legal action. The FDA had already concluded a new study that showed a disproportionate risk for those patients using Actos for Type-2 diabetes versus Avandia or other medications to show signs of developing bladder cancer. However to this day the FDA has not included this warning on the label of Actos.
In June of 2011, partly in response to the European studies, the FDA issued a new report for physicians indicating a possible link between Actos and bladder cancer. Doctors are advised not to prescribe this medication for those already afflicted with this disease.
Contact Seeger Weiss Today
If you or someone you know has suffered complications from Actos, contact us today. Reporting your experience can help protect other people from being harmed by this dangerous drug, and you may be entitled to compensation for your injury. An experienced attorney with Seeger Weiss LLP will assist you in evaluating your claim. Attorney consultations incur no obligation on your part and all initial consultations are free of charge. Seeger Weiss LLP has office locations in New York, New Jersey, Pennsylvania and California.Free Case Evaluation
Seeger Weiss LLP is investigating allegations by the Justice Department that U.S. airlines may have unlawfully colluded to control the number of available seats on flights in order to drive up ticket [...]July 2, 2015 By: Seeger Weiss LLP read more
Results from a recent data mining study conducted at Houston Methodist and Stanford University, California, showed that patients using proton pump inhibitors face a significantly higher risk for suffering a heart attack [...]June 15, 2015 By: Seeger Weiss LLP read more
Experts at The University of Pittsburgh Medical Center and Ohio State University have called for more research into possible health risks of a potentially toxic chemical, gadolinium, remaining in brain tissue of [...]June 12, 2015 By: Seeger Weiss LLP read more